Using Radiomics to Predict Neoadjuvant Chemotherapy Efficacy and Postoperative Adjuvant Chemotherapy Benefit in Advanced Gastric Cancer: a Two-center Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Gastric Cancer
- Sponsor
- Fujian Medical University
- Enrollment
- 193
- Locations
- 1
- Primary Endpoint
- AUC for ICSS
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
Neoadjuvant chemotherapy (NC) is an important treatment for advanced gastric cancer (AGC). However, tools that effectively predict the efficacy of NC before treatment are lacking. Computed tomography images before and after NC were used to construct a deep learning-based radiomics signature to predict the efficacy of NC, prognoses and postoperative adjuvant chemotherapy benefit.
Detailed Description
Background: Neoadjuvant chemotherapy (NC) is an important treatment for advanced gastric cancer (AGC). However, tools that effectively predict the efficacy of NC before treatment are lacking. Methods: Computed tomography images before and after NC were used to construct a deep learning-based radiomics signature to predict the efficacy of NC, prognoses and postoperative adjuvant chemotherapy benefit. Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC). 193 patients with AGC from January 2010 to December 2018 in two different China university hospitals were included in this study. The before neoadjuvant chemotherapy imaging scoring system (BNCISS), imaging change scoring system before and after neoadjuvant chemotherapy (ICSS), which were constructed based on computed tomography images before after treatment.
Investigators
Chang-Ming Huang, Prof.
Principal Investigator
Fujian Medical University
Eligibility Criteria
Inclusion Criteria
- •Prospective collection and a retrospective analysis of patients seen from January 2010 to December 2018 at Fujian Medical University Union Hospital (FMUUH) and the First Hospital of Lanzhou University (FHLU) who were diagnosed with gastric adenocarcinoma and underwent radical resection
Exclusion Criteria
- •Patients with concurrent malignant disease, distant metastases, palliative resection, or gastric stump cancer were excluded.
Outcomes
Primary Outcomes
AUC for ICSS
Time Frame: 2022-01-01 to 2022-07-31
The predictive performance of imaging change scoring system before and after neoadjuvant chemotherapy (ICSS)
AUC for BNCISS
Time Frame: 2022-01-01 to 2022-07-31
The predictive performance of before neoadjuvant chemotherapy imaging scoring system (BNCISS)
Secondary Outcomes
- overall survival(2010-01-01 to 2022-07-31)
- disease free survival(2010-01-01 to 2022-07-31)